Literature DB >> 10218785

D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala.

A Javed1, M C Kamradt, L D Van de Kar, T S Gray.   

Abstract

The neurotransmitters expressed by neurons activated by D-fenfluramine (5 mg/kg, i.p.) were identified in the hypothalamus, amygdala and bed nucleus of the stria terminalis. Induction of Fos immunoreactivity following D-fenfluramine injection was used as an index of neuronal activation. To test whether D-fenfluramine activated neurons by releasing serotonin from the serotonergic nerve terminals, rats were pretreated with fluoxetine (10 mg/kg, i.p.), a serotonin reuptake inhibitor that prevents the release of serotonin stimulated by D-fenfluramine, 12 h before D-fenfluramine injection. The approximate percentages of peptidergic neurons that contained Fos immunoreactivity after D-fenfluramine administration were 94% of corticotropin-releasing factor and 22% of oxytocin cells in the paraventricular nucleus of the hypothalamus, 6% of oxytocin cells in the supraoptic nucleus of the hypothalamus, 36% of enkephalin and 15% of neurotensin cells in the central amygdaloid nucleus, and 19% of enkephalin and 9% of neurotensin cells in the bed nucleus of the stria terminalis. Fluoxetine pretreatment blocked Fos expression in corticotropin-releasing factor- and oxytocin-expressing cells in the hypothalamus, but not in enkephalin-and neurotensin-expressing cells located in the bed nucleus of the stria terminalis and central amygdaloid nucleus. D-Fenfluramine did not induce Fos immunoreactivity in vasopressin-, thyrotropin-releasing hormone-, somatostatin- and tyrosine hydroxylase-containing cells in the hypothalamus, and corticotropin-releasing factor-expressing cells in the central amygdaloid nucleus and bed nucleus of the stria terminalis. These results show that D-fenfluramine stimulates corticotropin-releasing factor- and oxytocin-expressing cells in the hypothalamus via serotonin release. The enkephalin- and neurotensin-expressing cells in the amygdala are activated by D-fenfluramine via non-serotonergic mechanisms. Induction of Fos expression by D-fenfluramine in restricted populations of cells suggests a selective activation of neuronal circuitry that is likely to be involved in the appetite suppressant effects of D-fenfluramine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218785     DOI: 10.1016/s0306-4522(98)00523-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Activation by serotonin and noradrenaline of vasopressin and oxytocin expression in the mouse paraventricular and supraoptic nuclei.

Authors:  Claire-Marie Vacher; Philippe Frétier; Christophe Créminon; André Calas; Hélène Hardin-Pouzet
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

2.  Serotonin mediated changes in corticotropin releasing factor mRNA expression and feeding behavior isolated to the hypothalamic paraventricular nuclei.

Authors:  Joanne P Boisvert; Tyler J Boschuetz; Jon M Resch; Christopher R Mueller; Sujean Choi
Journal:  Neurosci Lett       Date:  2011-05-11       Impact factor: 3.046

3.  Inhibition of the central extended amygdala by loud noise and restraint stress.

Authors:  Heidi E W Day; Scott Nebel; Sarah Sasse; Serge Campeau
Journal:  Eur J Neurosci       Date:  2005-01       Impact factor: 3.386

4.  5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells.

Authors:  L D Van de Kar; A Javed; Y Zhang; F Serres; D K Raap; T S Gray
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

Review 5.  Oxytocin and postpartum depression: delivering on what's known and what's not.

Authors:  Sohye Kim; Timothy A Soeken; Sara J Cromer; Sheila R Martinez; Leah R Hardy; Lane Strathearn
Journal:  Brain Res       Date:  2013-11-14       Impact factor: 3.252

Review 6.  Stress, sex, and addiction: potential roles of corticotropin-releasing factor, oxytocin, and arginine-vasopressin.

Authors:  Verónica Bisagno; Jean Lud Cadet
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

Review 7.  Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment.

Authors:  David A Slattery; Inga D Neumann
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-16

Review 8.  Oxytocin: Narrative Expert Review of Current Perspectives on the Relationship with Other Neurotransmitters and the Impact on the Main Psychiatric Disorders.

Authors:  Tudor Florea; Matei Palimariciuc; Ana Caterina Cristofor; Irina Dobrin; Roxana Chiriță; Magdalena Bîrsan; Romeo Petru Dobrin; Manuela Pădurariu
Journal:  Medicina (Kaunas)       Date:  2022-07-11       Impact factor: 2.948

9.  Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation.

Authors:  Lora K Heisler; Nina Pronchuk; Katsunori Nonogaki; Ligang Zhou; Jacob Raber; Loraine Tung; Giles S H Yeo; Stephen O'Rahilly; William F Colmers; Joel K Elmquist; Laurence H Tecott
Journal:  J Neurosci       Date:  2007-06-27       Impact factor: 6.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.